(2S,3R)-3-Hydroxy-5-[4-(6-methoxypyridin-3-yl)phenyl]-2-[2-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]pentanoic acid | 908333-77-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (2S,3R)-3-Hydroxy-5-[4-(6-methoxypyridin-3-yl)phenyl]-2-[2-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]pentanoic acid
• 英文别名: (2S,3R)-3-hydroxy-5-[4-(6-methoxypyridin-3-yl)phenyl]-2-[2-(4-oxo-1,2,3-benzotriazin-3-yl)ethyl]pentanoic acid
• CAS: 908333-77-7
• 化学式: C₂₆H₂₆N₄O₅
• 分子量: 474.516
• InChiKey: KPCMEBADOSLVLZ-JTHBVZDNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  35
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  125
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (2S,3R)-3-Hydroxy-5-[4-(6-methoxypyridin-3-yl)phenyl]-2-[2-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]pentanoic acid 在 三溴化硼 、 水 作用下， 以 甲苯 、 乙酸乙酯 为溶剂， 反应 4.0h， 生成 (2S,3R)-3-hydroxy-5-[4-(6-hydroxypyridin-3-yl)phenyl]-2-[2-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]pentanoic acid
  参考文献：
  名称：

  WO2008/23336

  摘要：

  公开号：
• 作为产物：
  描述：

  (2S,3R)-3-(formyloxy)-5-[4-(6-methoxypyridin-3-yl)phenyl]-2-[2-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]pentanoic acid 在 甲醇 、 potassium carbonate 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 (2S,3R)-3-Hydroxy-5-[4-(6-methoxypyridin-3-yl)phenyl]-2-[2-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]pentanoic acid
  参考文献：
  名称：

  WO2008/23336

  摘要：

  公开号：

文献信息

• 5-Phenyl-Pentanoic Acid Derivatives as Matrix Metalloproteinase Inhibitors for the Treatment of Asthma and Other Diseases
  申请人：Palle Venkata P.

  公开号：US20080194565A1

  公开（公告）日：2008-08-14

  The present invention relates to C ompounds having the structure of Formula I: wherein n is an integer from 1 to 5; R 1 is optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, alkoxy, aryloxy, alkenyloxy or alkynyloxy; R 2 is alkenyl, allcynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, NR 4 R 5 , —NHC(═Y)R 4 , —NHC(═Y)NR 5 R x , —NHC(═O)OR 4 , —NHSO 2 R 4 , C(═Y)NR 4 R 5 , C(═O)OR 6 [wherein Y is oxygen or sulphur], OR 5 , —O(C═O)NR 4 R 5 , O-acyl, S(O) m R 4 , —SO 2 N(R 4 ) 2 , cyano, amidino or guanidino [wherein R 4 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heteroarylalkyl, heterocyclylalkyl or cycloalkylalkyl and m is an integer 0-2; R 5 is hydrogen or R 4 ; R x is R 4 or —SO 2 N(R 4 ) 2 and R 6 is hydrogen, alkyl, cycloalkyl, aralkyl, heteroarylalkyl, heterocyclylalkyl or cycloalkylalkyl]; R 3 is hydrogen, fluorine, alkyl, cycloalkylalkyl or aralkyl; A is OH, OR 4 , —OC(═O)NR 4 R 5 , O-acyl, NH 2 , NR 4 R 5 , —NHC(═Y)R 4 , —NHC(═Y)NR 5 R x , —NHC(═O)OR 4 , —NHSO 2 R 4 , and to processes for the synthesis of the same. This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by over-expression and over-activation of an matrix metalloproteinase, using the compounds.

  本发明涉及具有以下结构的化合物：其中n是1到5之间的整数；R1是可选择地取代的烷基、烯基、炔基、环烷基、芳基、杂环烷基、杂芳基、芳基烷基、烷氧基、芳氧基、烯基氧基或炔基氧基；R2是烯基、炔基、芳基、杂环烷基、杂芳基、环烷基、NR4R5、—NHC(═Y)R4、—NHC(═Y)NR5Rx、—NHC(═O)OR4、—NHSO2R4、C(═Y)NR4R5、C(═O)OR6[其中Y是氧或硫]、OR5、—O(C═O)NR4R5、O-酰基、S(O)mR4、—SO2N(R4)2、氰基、胺基亚胺基或胍基[其中R4是烷基、烯基、炔基、环烷基、芳基、杂环烷基、杂芳基、芳基烷基、杂芳基烷基、杂环烷基烷基或环烷基烷基，m是0-2的整数；R5是氢或R4；Rx是R4或—SO2N(R4)2，R6是氢、烷基、环烷基、芳基烷基、杂芳基烷基、杂环烷基烷基或环烷基烷基]；R3是氢、氟、烷基、环烷基烷基或芳基烷基；A是OH、OR4、—OC(═O)NR4R5、O-酰基、NH2、NR4R5、—NHC(═Y)R4、—NHC(═Y)NR5Rx、—NHC(═O)OR4、—NHSO2R4等，以及其合成方法。本发明还涉及含有本发明化合物的药理学组合物，以及治疗哮喘、类风湿关节炎、慢性阻塞性肺病、鼻炎、骨关节炎、银屑病性关节炎、牛皮癣、肺纤维化、肺部炎症、急性呼吸窘迫综合征、牙周炎、多发性硬化症、牙龈炎、动脉粥样硬化、新生内膜增生导致再狭窄和缺血性心力衰竭、中风、肾脏疾病、肿瘤转移和其他炎症性疾病的方法，这些疾病特征是矩阵金属蛋白酶的过度表达和过度激活，使用这些化合物。
• MATRIX METALLOPROTEINASE INHIBITORS
  申请人：Sattigeri Viswajanani J.

  公开号：US20100081610A1

  公开（公告）日：2010-04-01

  The present invention relates to β-hydroxy and amino substituted carboxylic acids, which act as matrix metalloprotease inhibitors, particularly diastereomerically pure β-hydroxy carboxylic acids, corresponding processes for the synthesis of and pharmaceutical compositions containing the compounds of the present invention. Compounds of the present invention are useful in the treatment of various inflammatory, autoimmune and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase using the compounds.

  本发明涉及β-羟基和氨基取代的羧酸，其作为基质金属蛋白酶抑制剂，尤其是对映异构体纯的β-羟基羧酸，以及合成该类化合物和含有本发明化合物的制药组合物的相关过程。本发明化合物在治疗各种炎症、自身免疫和过敏性疾病方面有用，例如治疗哮喘、类风湿性关节炎、慢性阻塞性肺疾病、鼻炎、骨关节炎、银屑病性关节炎、牛皮癣、肺纤维化、创伤愈合障碍、肺炎炎症、急性呼吸窘迫综合征、牙周炎、多发性硬化症、牙龈炎、动脉粥样硬化、新内膜增生导致再狭窄和缺血性心力衰竭、中风、肾脏疾病、肿瘤转移以及其他以基质金属蛋白酶过度表达和过度活化为特征的炎症性疾病的方法中使用该化合物。
• Matrix metalloproteinase inhibitors
  申请人：Sattigeri Viswajanani J.

  公开号：US08507670B2

  公开（公告）日：2013-08-13

  The present invention relates to β-hydroxy and amino substituted carboxylic acids, which act as matrix metalloprotease inhibitors, particularly diastereomerically pure β-hydroxy carboxylic acids, corresponding processes for the synthesis of and pharmaceutical compositions containing the compounds of the present invention. Compounds of the present invention are useful in the treatment of various inflammatory, autoimmune and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, periodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase using the compounds.

  本发明涉及β-羟基和氨基取代的羧酸，其作为基质金属蛋白酶抑制剂，特别是对映异构体纯的β-羟基羧酸，以及合成这些化合物的相应过程和含有本发明化合物的制药组合物。本发明化合物在治疗各种炎症、自身免疫和过敏性疾病方面有用，例如治疗哮喘、类风湿关节炎、慢性阻塞性肺病、鼻炎、骨关节炎、银屑病性关节炎、牛皮癣、肺纤维化、创伤愈合障碍、肺部炎症、急性呼吸窘迫综合征、牙周炎、多发性硬化症、牙龈炎、动脉粥样硬化、新内膜增生导致再狭窄和缺血性心力衰竭、中风、肾脏疾病、肿瘤转移和其他基质金属蛋白酶过度表达和过度活化的炎症性疾病中使用这些化合物的方法。
• LOW PROTONATION CONSTANT HYDROXY ACIDS
  申请人：Rehnberg Nicola

  公开号：US20090155481A1

  公开（公告）日：2009-06-18

  The present invention relates to a hydroxy-sulphureous acid, to a method for preparation of the hydroxysulphureous acid and to products based on said hydroxysulphureous acid, to methods for preparation of said products and to use of said products, wherein said hydroxysulphureous acid is used as building blocks for polymer systems, e g aqueous polymer systems such as inks, coatings, and adhesives.

  本发明涉及一种羟基硫酸，一种制备该羟基硫酸的方法以及基于该羟基硫酸的产品，制备该产品的方法以及该产品的用途。其中，该羟基硫酸被用作聚合物体系的构建块，例如水性聚合物体系，如油墨、涂料和粘合剂。
• 5-PHENYL-PENTANOIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FOR THE TREATMENT OF ASTHMA AND OTHER DISEASES
  申请人：Ranbaxy Laboratories Limited

  公开号：EP1856063A1

  公开（公告）日：2007-11-21